In a previous study carried out on a large group of melanoma patients and based on serum proteomic analysis and immunoassays, we established prognostic value of serum dermcidin (DCD) for stage II melanoma patients (Ortega‐Martínez et al., 2016). This evidence concerns the gene DCD and melanoma.